Public private partnerships and emerging technologies: A look at nanomedicine for diseases of poverty

Thomas S. Woodson

Research Policy, 2016, vol. 45, issue 7, 1410-1418

Abstract: Emerging technologies, like nanotechnology, are often hailed as transformative technologies that will not only help the rich, but be used to decrease poverty and inequality. In order to overcome many of the challenges associated with developing products for poor communities, especially medicines for the poor, institutions setup organizations called public private partnership (PPPs). This study examines whether PPPs are developing nanotechnology to make medicines for diseases of poverty (DoP). PPPs are the main actors researching medicines for DoP and if they are not involved with nanotechnology research, then it is unlikely that nanomedicines for DoP will be developed. Through interviews and website content analysis, this study finds that there are only a few PPPs doing nanomedicine research. Many of the PPPs are worried that the technology is too expensive and it will take too long to bring nanomedicines to the market. To increase the likelihood that emerging technologies, like nanotechnology, will be used to mitigate poverty, policy makers can do several things like change the patent laws to encourage innovation on technologies for the poor, increase research funding in areas that address development, and move pro-poor technologies quickly through the regulation process.

Keywords: Public private partnership; Emerging technologies; Nanotechnology; Diseases of poverty; Inclusive innovation (search for similar items in EconPapers)
Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (10)

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0048733316300518
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:respol:v:45:y:2016:i:7:p:1410-1418

DOI: 10.1016/j.respol.2016.04.005

Access Statistics for this article

Research Policy is currently edited by M. Bell, B. Martin, W.E. Steinmueller, A. Arora, M. Callon, M. Kenney, S. Kuhlmann, Keun Lee and F. Murray

More articles in Research Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu ().